-
1
-
-
0025120211
-
Regulation of the mevalonate pathway
-
Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990;343:425-30.
-
(1990)
Nature
, vol.343
, pp. 425-430
-
-
Goldstein, J.L.1
Brown, M.S.2
-
3
-
-
28844490054
-
Statins and cancer prevention
-
DOI 10.1038/nrc1751
-
Demierre MF, Higgins PD, Gruber SB, Hawk E, Lippman SM. Statins and cancer prevention. Nat Rev Cancer 2005;5:930-42. (Pubitemid 41766782)
-
(2005)
Nature Reviews Cancer
, vol.5
, Issue.12
, pp. 930-942
-
-
Demierre, M.-F.1
Higgins, P.D.R.2
Gruber, S.B.3
Hawk, E.4
Lippman, S.M.5
-
4
-
-
0036729485
-
American society of clinical oncology clinical practice guidelines: The role of bisphosphonates in multiple myeloma
-
DOI 10.1200/JCO.2002.06.037
-
Berenson JR, Hillner BE, Kyle RA, Anderson K, Lipton A, Yee GC, et al. American Society of Clinical Oncology Bisphosphonates Expert Panel. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol 2002; 20:3719-36. (Pubitemid 34983232)
-
(2002)
Journal of Clinical Oncology
, vol.20
, Issue.17
, pp. 3719-3736
-
-
Berenson, J.R.1
Hillner, B.E.2
Kyle, R.A.3
Anderson, K.4
Lipton, A.5
Yee, G.C.6
Biermann, J.S.7
-
5
-
-
34347369084
-
Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets
-
DOI 10.1038/nrd2221, PII NRD2221
-
Konstantinopoulos PA, Karamouzis MV, Papavassiliou AG. Posttranslational modifications and regulation of the RAS superfamily of GTPases as anticancer targets. Nat Rev Drug Discov 2007;6:541-55. (Pubitemid 47019443)
-
(2007)
Nature Reviews Drug Discovery
, vol.6
, Issue.7
, pp. 541-555
-
-
Konstantinopoulos, P.A.1
Karamouzis, M.V.2
Papavassiliou, A.G.3
-
6
-
-
33646354412
-
Statin therapy and autoimmune disease: From protein prenylation to immunomodulation
-
Greenwood J, Steinman L, Zamvil SS. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat Rev Immunol 2006;6:358-70.
-
(2006)
Nat Rev Immunol
, vol.6
, pp. 358-370
-
-
Greenwood, J.1
Steinman, L.2
Zamvil, S.S.3
-
7
-
-
77955758944
-
Novel bone-targeted strategies in oncology
-
Vallet S, Smith MR, Raje N. Novel bone-targeted strategies in oncology. Clin Cancer Res 2010;16:4084-93.
-
(2010)
Clin Cancer Res
, vol.16
, pp. 4084-4093
-
-
Vallet, S.1
Smith, M.R.2
Raje, N.3
-
8
-
-
0036239832
-
HMG-CoA reductase inhibitors and the malignant cell: The statin family of drugs as triggers of tumor-specific apoptosis
-
DOI 10.1038/sj/leu/2402476
-
Wong WW, Dimitroulakos J, Minden MD, Penn LZ. HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 2002;16:508-19. (Pubitemid 34460459)
-
(2002)
Leukemia
, vol.16
, Issue.4
, pp. 508-519
-
-
Wong, W.W.-L.1
Dimitroulakos, J.2
Minden, M.D.3
Penn, L.Z.4
-
9
-
-
2942754163
-
The risk of cancer in users of statins
-
DOI 10.1200/JCO.2004.02.027
-
Graaf MR, Beiderbeck AB, Egberts AC, Richel DJ, Guchelaar HJ. The risk of cancer in users of statins. J Clin Oncol 2004;22:2388-94. (Pubitemid 41115396)
-
(2004)
Journal of Clinical Oncology
, vol.22
, Issue.12
, pp. 2388-2394
-
-
Graaf, M.R.1
Beiderbeck, A.B.2
Egberts, A.C.G.3
Richel, D.J.4
Guchelaar, H.-J.5
-
10
-
-
19444364509
-
Statins and the risk of colorectal cancer
-
DOI 10.1056/NEJMoa043792
-
Poynter JN, Gruber SB, Higgins PD, Almog R, Bonner JD, Rennert HS, et al. Statins and the risk of colorectal cancer. N Engl J Med 2005;352:2184-92. (Pubitemid 40727085)
-
(2005)
New England Journal of Medicine
, vol.352
, Issue.21
, pp. 2184-2192
-
-
Poynter, J.N.1
Gruber, S.B.2
Higgins, P.D.R.3
Almog, R.4
Bonner, J.D.5
Rennert, H.S.6
Low, M.7
Greenson, J.K.8
Rennert, G.9
-
11
-
-
77954756757
-
Exploiting the mevalonate pathway to distinguish statin-sensitive multiple myeloma
-
Clendening JW, Pandyra A, Li Z, Boutros PC, Martirosyan A, Lehner R, et al. Exploiting the mevalonate pathway to distinguish statin-sensitive multiple myeloma. Blood 2010;115:4787-97.
-
(2010)
Blood
, vol.115
, pp. 4787-4797
-
-
Clendening, J.W.1
Pandyra, A.2
Li, Z.3
Boutros, P.C.4
Martirosyan, A.5
Lehner, R.6
-
12
-
-
33947594969
-
Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: A phase 1 study
-
DOI 10.1182/blood-2006-08-044446
-
Kornblau SM, Banker DE, Stirewalt D, Shen D, Lemker E, Verstovsek S, et al. Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study. Blood 2007;109:2999-3006. (Pubitemid 46482100)
-
(2007)
Blood
, vol.109
, Issue.7
, pp. 2999-3006
-
-
Kornblau, S.M.1
Banker, D.E.2
Stirewalt, D.3
Shen, D.4
Lemker, E.5
Verstovsek, S.6
Estrov, Z.7
Faderl, S.8
Cortes, J.9
Beran, M.10
Jackson, C.E.11
Chen, W.12
Estey, E.13
Appelbaum, F.R.14
-
13
-
-
84862908644
-
Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway
-
Freed-Pastor WA, Mizuno H, Zhao X, Langerød A, Moon SH, Rodriguez-Barrueco R, et al. Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell 2012;148:244-58.
-
(2012)
Cell
, vol.148
, pp. 244-258
-
-
Freed-Pastor, W.A.1
Mizuno, H.2
Zhao, X.3
Langerød, A.4
Moon, S.H.5
Rodriguez-Barrueco, R.6
-
14
-
-
77955881211
-
Can oral bisphosphonates really reduce the risk of breast cancer in healthy women?
-
Gnant M. Can oral bisphosphonates really reduce the risk of breast cancer in healthy women? J Clin Oncol 2010;28:3548-51.
-
(2010)
J Clin Oncol
, vol.28
, pp. 3548-3551
-
-
Gnant, M.1
-
15
-
-
33644666787
-
Bisphosphonates for treatment and prevention of bone metastases
-
DOI 10.1200/JCO.2005.02.9579
-
Michaelson MD, Smith MR. Bisphosphonates for treatment and prevention of bone metastases. J Clin Oncol 2005;23:8219-24. (Pubitemid 46211558)
-
(2005)
Journal of Clinical Oncology
, vol.23
, Issue.32
, pp. 8219-8224
-
-
Michaelson, M.D.1
Smith, M.R.2
-
16
-
-
30844467746
-
Lipid posttranslational modifications. Farnesyl transferase inhibitors
-
Basso AD, Kirschmeier P, Bishop WR. Lipid posttranslational modifications. Farnesyl transferase inhibitors. J Lipid Res 2006;47: 15-31.
-
(2006)
J Lipid Res
, vol.47
, pp. 15-31
-
-
Basso, A.D.1
Kirschmeier, P.2
Bishop, W.R.3
-
17
-
-
0027248872
-
Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor
-
Kohl NE, Mosser SD, deSolms SJ, Giuliani EA, Pompliano DL, Graham SL, et al. Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science 1993;260:1934-7. (Pubitemid 23258273)
-
(1993)
Science
, vol.260
, Issue.5116
, pp. 1934-1937
-
-
Kohl, N.E.1
Mosser, S.D.2
DeSolms, S.J.3
Giuliani, E.A.4
Pompliano, D.L.5
Graham, S.L.6
Smith, R.L.7
Scolnick, E.M.8
Oliff, A.9
Gibbs, J.B.10
-
18
-
-
16544382706
-
Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies
-
Zimmerman TM, Harlin H, Odenike OM, Berk S, Sprague E, Karrison T, et al. Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies. J Clin Oncol 2004;22:4816-22.
-
(2004)
J Clin Oncol
, vol.22
, pp. 4816-4822
-
-
Zimmerman, T.M.1
Harlin, H.2
Odenike, O.M.3
Berk, S.4
Sprague, E.5
Karrison, T.6
-
19
-
-
33847001315
-
A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia
-
DOI 10.1182/blood-2006-04-014357
-
Lancet JE, Gojo I, Gotlib J, Feldman EJ, Greer J, Liesveld JL, et al. A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. Blood 2007;109:1387-94. (Pubitemid 46242109)
-
(2007)
Blood
, vol.109
, Issue.4
, pp. 1387-1394
-
-
Lancet, J.E.1
Gojo, I.2
Gotlib, J.3
Feldman, E.J.4
Greer, J.5
Liesveld, J.L.6
Bruzek, L.M.7
Morris, L.8
Park, Y.9
Adjei, A.A.10
Kaufmann, S.H.11
Garrett-Mayer, E.12
Greenberg, P.L.13
Wright, J.J.14
Karp, J.E.15
-
20
-
-
18744363084
-
Isoprenylation of intracellular proteins as a new target for the therapy of human neoplasms: Preclinical and clinical implications
-
DOI 10.2174/1389450053765833
-
Caraglia M, Budillon A, Tagliaferri P, Marra M, Abbruzzese A, Caponigro F. Isoprenylation of intracellular proteins as a new target for the therapy of human neoplasms: preclinical and clinical implications. Curr Drug Targets 2005;6:301-23. (Pubitemid 40667797)
-
(2005)
Current Drug Targets
, vol.6
, Issue.3
, pp. 301-323
-
-
Caraglia, M.1
Budillon, A.2
Tagliaferri, P.3
Marra, M.4
Abbruzzese, A.5
Caponigro, F.6
-
21
-
-
0035364973
-
Inhibition of protein farnesylation enhances the chemotherapeutic efficacy of the novel geranylgeranyltransferase inhibitor BAL9611 in human colon cancer cells
-
DOI 10.1054/bjoc.2001.1820
-
Di Paolo A, Danesi R, Caputo S, Macchia M, Lastella M, Boggi U, et al. Inhibition of protein farnesylation enhances the chemotherapeutic efficacy of the novel geranylgeranyltransferase inhibitor BAL9611 in human colon cancer cells. Br J Cancer 2001;84:1535-43. (Pubitemid 32579347)
-
(2001)
British Journal of Cancer
, vol.84
, Issue.11
, pp. 1535-1543
-
-
Di, P.A.1
Danesi, R.2
Caputo, S.3
Macchia, M.4
Lastella, M.5
Boggi, U.6
Mosca, F.7
Marchetti, A.8
Del, T.M.9
-
22
-
-
77953809435
-
Membrane targeting mechanism of Rab GTPases elucidated by semisynthetic protein probes
-
Wu YW, Oesterlin LK, Tan KT, Waldmann H, Alexandrov K, Goody RS. Membrane targeting mechanism of Rab GTPases elucidated by semisynthetic protein probes. Nat Chem Biol 2010;6:534-40.
-
(2010)
Nat Chem Biol
, vol.6
, pp. 534-540
-
-
Wu, Y.W.1
Oesterlin, L.K.2
Tan, K.T.3
Waldmann, H.4
Alexandrov, K.5
Goody, R.S.6
-
24
-
-
22244446505
-
The mammalian unfolded protein response
-
DOI 10.1146/annurev.biochem.73.011303.074134
-
Schröder M, Kaufman RJ. The mammalian unfolded protein response. Annu Rev Biochem 2005;74:739-89. (Pubitemid 40995523)
-
(2005)
Annual Review of Biochemistry
, vol.74
, pp. 739-789
-
-
Schroder, M.1
Kaufman, R.J.2
-
25
-
-
51749116326
-
HMG-CoA reductase inhibitors activate the unfolded protein response and induce cytoprotective GRP78 expression
-
Chen JC, Wu ML, Huang KC, Lin WW. HMG-CoA reductase inhibitors activate the unfolded protein response and induce cytoprotective GRP78 expression. Cardiovasc Res 2008;80:138-50.
-
(2008)
Cardiovasc Res
, vol.80
, pp. 138-150
-
-
Chen, J.C.1
Wu, M.L.2
Huang, K.C.3
Lin, W.W.4
-
26
-
-
57049117856
-
Cell death and endoplasmic reticulum stress: Disease relevance and therapeutic opportunities
-
Kim I, Xu W, Reed JC. Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities. Nat Rev Drug Discov 2008;7:1013-30.
-
(2008)
Nat Rev Drug Discov
, vol.7
, pp. 1013-1030
-
-
Kim, I.1
Xu, W.2
Reed, J.C.3
-
27
-
-
37649005234
-
Autophagy in the pathogenesis of disease
-
Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell 2008;132:27-42.
-
(2008)
Cell
, vol.132
, pp. 27-42
-
-
Levine, B.1
Kroemer, G.2
-
28
-
-
33845459165
-
Autophagy is activated for cell survival after endoplasmic reticulum stress
-
DOI 10.1128/MCB.01453-06
-
Ogata M, Hino S, Saito A, Morikawa K, Kondo S, Kanemoto S, et al. Autophagy is activated for cell survival after endoplasmic reticulum stress. Mol Cell Biol 2006;26:9220-31. (Pubitemid 44904418)
-
(2006)
Molecular and Cellular Biology
, vol.26
, Issue.24
, pp. 9220-9231
-
-
Ogata, M.1
Hino, S.-I.2
Saito, A.3
Morikawa, K.4
Kondo, S.5
Kanemoto, S.6
Murakami, T.7
Taniguchi, M.8
Tanii, I.9
Yoshinaga, K.10
Shiosaka, S.11
Hammarback, J.A.12
Urano, F.13
Imaizumi, K.14
-
29
-
-
43249109174
-
Endoplasmic reticulum stress responses
-
Schröder M. Endoplasmic reticulum stress responses. Cell Mol Life Sci 2008;65:862-94.
-
(2008)
Cell Mol Life Sci
, vol.65
, pp. 862-894
-
-
Schröder, M.1
-
30
-
-
79951642032
-
Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome
-
Nakahira K, Haspel JA, Rathinam VA, Lee SJ, Dolinay T, Lam HC, et al. Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome. Nat Immunol 2011;12:222-30.
-
(2011)
Nat Immunol
, vol.12
, pp. 222-230
-
-
Nakahira, K.1
Haspel, J.A.2
Rathinam, V.A.3
Lee, S.J.4
Dolinay, T.5
Lam, H.C.6
-
31
-
-
84857195479
-
Activation of autophagy by inflammatory signals limits IL-1b production by targeting ubiquitinated inflammasomes for destruction
-
Shi CS, Shenderov K, Huang NN, Kabat J, Abu-Asab M, Fitzgerald KA, et al. Activation of autophagy by inflammatory signals limits IL-1b production by targeting ubiquitinated inflammasomes for destruction. Nat Immunol 2012;13:255-63.
-
(2012)
Nat Immunol
, vol.13
, pp. 255-263
-
-
Shi, C.S.1
Shenderov, K.2
Huang, N.N.3
Kabat, J.4
Abu-Asab, M.5
Fitzgerald, K.A.6
-
32
-
-
0032497364
-
Mechanism of Rab geranylgeranylation: Formation of the catalytic ternary complex
-
DOI 10.1021/bi980881a
-
Anant JS, Desnoyers L, Machius M, Demeler B, Hansen JC, Westover KD, et al. Mechanism of Rab geranylgeranylation: formation of the catalytic ternary complex. Biochemistry 1998;37:12559-68. (Pubitemid 28427540)
-
(1998)
Biochemistry
, vol.37
, Issue.36
, pp. 12559-12568
-
-
Anant, J.S.1
Desnoyers, L.2
Machius, M.3
Demeler, B.4
Hansen, J.C.5
Westover, K.D.6
Deisenhofer, J.7
Seabra, M.C.8
-
33
-
-
67549139908
-
Vesicular trafficking and autophagosome formation
-
Longatti A, Tooze SA. Vesicular trafficking and autophagosome formation. Cell Death Differ 2009;16:956-65.
-
(2009)
Cell Death Differ
, vol.16
, pp. 956-965
-
-
Longatti, A.1
Tooze, S.A.2
-
34
-
-
73349108071
-
CD56 +human blood dendritic cells effectively promote TH1-type gammadelta T-cell responses
-
Gruenbacher G, Gander H, Rahm A, Nussbaumer W, Romani N, Thurnher M. CD56 +human blood dendritic cells effectively promote TH1-type gammadelta T-cell responses. Blood 2009;114:4422-31.
-
(2009)
Blood
, vol.114
, pp. 4422-4431
-
-
Gruenbacher, G.1
Gander, H.2
Rahm, A.3
Nussbaumer, W.4
Romani, N.5
Thurnher, M.6
-
35
-
-
34848837386
-
Taking dendritic cells into medicine
-
DOI 10.1038/nature06175, PII NATURE06175
-
Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature 2007;449:419-26. (Pubitemid 47509552)
-
(2007)
Nature
, vol.449
, Issue.7161
, pp. 419-426
-
-
Steinman, R.M.1
Banchereau, J.2
-
36
-
-
78649964343
-
IL-2 costimulation enables statin-mediated activation of human NK cells, preferentially through a mechanism involving CD56+ dendritic cells
-
Gruenbacher G, Gander H, Nussbaumer O, Nussbaumer W, Rahm A, Thurnher M. IL-2 costimulation enables statin-mediated activation of human NK cells, preferentially through a mechanism involving CD56+ dendritic cells. Cancer Res 2010;70:9611-20.
-
(2010)
Cancer Res
, vol.70
, pp. 9611-9620
-
-
Gruenbacher, G.1
Gander, H.2
Nussbaumer, O.3
Nussbaumer, W.4
Rahm, A.5
Thurnher, M.6
-
37
-
-
22944486712
-
Dendritic cell maturation by innate lymphocytes: Coordinated stimulation of innate and adaptive immunity
-
DOI 10.1084/jem.20050810
-
Münz C, Steinman RM, Fujii S. Dendritic cell maturation by innate lymphocytes: coordinated stimulation of innate and adaptive immunity. J Exp Med 2005;202:203-7. (Pubitemid 41043815)
-
(2005)
Journal of Experimental Medicine
, vol.202
, Issue.2
, pp. 203-207
-
-
Munz, C.1
Steinman, R.M.2
Fujii, S.-I.3
-
38
-
-
77956593114
-
Human gammadelta T lymphocytes induce robust NK cell-mediated antitumor cytotoxicity through CD137 engagement
-
Maniar A, Zhang X, Lin W, Gastman BR, Pauza CD, Strome SE, et al. Human gammadelta T lymphocytes induce robust NK cell-mediated antitumor cytotoxicity through CD137 engagement. Blood 2010;116: 1726-33.
-
(2010)
Blood
, vol.116
, pp. 1726-1733
-
-
Maniar, A.1
Zhang, X.2
Lin, W.3
Gastman, B.R.4
Pauza, C.D.5
Strome, S.E.6
-
39
-
-
0033522147
-
Gamma/delta T-cell stimulation by pamidronate
-
Kunzmann V, Bauer E, Wilhelm M. Gamma/delta T-cell stimulation by pamidronate. N Engl J Med 1999;340:737-8.
-
(1999)
N Engl J Med
, vol.340
, pp. 737-738
-
-
Kunzmann, V.1
Bauer, E.2
Wilhelm, M.3
-
40
-
-
33846804360
-
Nonpeptide antigens, presentation mechanisms, and immunological memory of human Vgamma2Vdelta2 T cells: Discriminating friend from foe through the recognition of prenyl pyrophosphate antigens
-
DOI 10.1111/j.1600-065X.2006.00479.x
-
Morita CT, Jin C, Sarikonda G, Wang H. Nonpeptide antigens, presentation mechanisms, and immunological memory of human Vgamma2Vdelta2 T cells: discriminating friend from foe through the recognition of prenyl pyrophosphate antigens. Immunol Rev 2007;215: 59-76. (Pubitemid 46212230)
-
(2007)
Immunological Reviews
, vol.215
, Issue.1
, pp. 59-76
-
-
Morita, C.T.1
Jin, C.2
Sarikonda, G.3
Wang, H.4
-
41
-
-
33846454363
-
Perspectives of gammadelta T cells in tumor immunology
-
DOI 10.1158/0008-5472.CAN-06-3069
-
Kabelitz D, Wesch D, He W. Perspectives of gammadelta T cells in tumor immunology. Cancer Res 2007;67:5-8. (Pubitemid 46142752)
-
(2007)
Cancer Research
, vol.67
, Issue.1
, pp. 5-8
-
-
Kabelitz, D.1
Wesch, D.2
He, W.3
-
42
-
-
37049006066
-
Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma
-
DOI 10.1158/0008-5472.CAN-07-1882
-
Melani C, Sangaletti S, Barazzetta FM, Werb Z, Colombo MP. Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. Cancer Res 2007;67:11438-46. (Pubitemid 350248572)
-
(2007)
Cancer Research
, vol.67
, Issue.23
, pp. 11438-11446
-
-
Melani, C.1
Sangaletti, S.2
Barazzetta, F.M.3
Werb, Z.4
Colombo, M.P.5
-
43
-
-
78650051896
-
Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway
-
Coscia M, Quaglino E, Iezzi M, Curcio C, Pantaleoni F, Riganti C, et al. Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. J Cell Mol Med 2010;14:2803-15.
-
(2010)
J Cell Mol Med
, vol.14
, pp. 2803-2815
-
-
Coscia, M.1
Quaglino, E.2
Iezzi, M.3
Curcio, C.4
Pantaleoni, F.5
Riganti, C.6
-
44
-
-
77955982989
-
Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma
-
Veltman JD, Lambers ME, van Nimwegen M, Hendriks RW, Hoogsteden HC, Hegmans JP, et al. Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma. Br J Cancer 2010;103:629-41.
-
(2010)
Br J Cancer
, vol.103
, pp. 629-641
-
-
Veltman, J.D.1
Lambers, M.E.2
Van Nimwegen, M.3
Hendriks, R.W.4
Hoogsteden, H.C.5
Hegmans, J.P.6
-
45
-
-
33748804427
-
The effect of zoledronic acid on the function and differentiation of myeloid cells
-
Wolf AM, Rumpold H, Tilg H, Gastl G, Gunsilius E, Wolf D. The effect of zoledronic acid on the function and differentiation of myeloid cells. Haematologica 2006;91:1165-71. (Pubitemid 44408425)
-
(2006)
Haematologica
, vol.91
, Issue.9
, pp. 1165-1171
-
-
Wolf, A.M.1
Rumpold, H.2
Tilg, H.3
Gastl, G.4
Gunsilius, E.5
Wolf, D.6
-
46
-
-
33947383077
-
Zoledronic acid inhibits the function of Toll-like receptor 4 ligand activated monocyte-derived dendritic cells
-
DOI 10.1038/sj.leu.2404556, PII 2404556
-
Bringmann A, Schmidt SM, Weck MM, Brauer KM, von Schwarzenberg K, Werth D, et al. Zoledronic acid inhibits the function of Toll-like receptor 4 ligand activated monocyte-derived dendritic cells. Leukemia 2007;21:732-8. (Pubitemid 46444557)
-
(2007)
Leukemia
, vol.21
, Issue.4
, pp. 732-738
-
-
Bringmann, A.1
Schmidt, S.M.2
Weck, M.M.3
Brauer, K.M.4
Von, S.K.5
Werth, D.6
Grunebach, F.7
Brossart, P.8
-
47
-
-
80052674947
-
DC-like cell-dependent activation of human natural killer cells by the bisphosphonate zoledronic acid is regulated by gd T lymphocytes
-
Nussbaumer O, Gruenbacher G, Gander H, Thurnher M. DC-like cell-dependent activation of human natural killer cells by the bisphosphonate zoledronic acid is regulated by gd T lymphocytes. Blood 2011; 118:2743-51.
-
(2011)
Blood
, vol.118
, pp. 2743-2751
-
-
Nussbaumer, O.1
Gruenbacher, G.2
Gander, H.3
Thurnher, M.4
-
48
-
-
78650961487
-
Activation of the unfolded protein response and autophagy after hepatitis C virus infection suppresses innate antiviral immunity in vitro
-
Ke PY, Chen SS. Activation of the unfolded protein response and autophagy after hepatitis C virus infection suppresses innate antiviral immunity in vitro. J Clin Invest 2011;121:37-56.
-
(2011)
J Clin Invest
, vol.121
, pp. 37-56
-
-
Ke, P.Y.1
Chen, S.S.2
-
49
-
-
77953806728
-
The inhibition of mevalonate pathway induces upregulation of NALP3 expression: New insight in the pathogenesis of mevalonate kinase deficiency
-
Pontillo A, Paoluzzi E, Crovella S. The inhibition of mevalonate pathway induces upregulation of NALP3 expression: new insight in the pathogenesis of mevalonate kinase deficiency. Eur J Hum Genet 2010;18:844-7.
-
(2010)
Eur J Hum Genet
, vol.18
, pp. 844-847
-
-
Pontillo, A.1
Paoluzzi, E.2
Crovella, S.3
-
50
-
-
62649139025
-
Immunological and inflammatory functions of the interleukin- 1 family
-
Dinarello CA. Immunological and inflammatory functions of the interleukin- 1 family. Annu Rev Immunol 2009;27:519-50.
-
(2009)
Annu Rev Immunol
, vol.27
, pp. 519-550
-
-
Dinarello, C.A.1
-
51
-
-
0034283671
-
Simvastatin modulates cytokine-mediated endothelial cell adhesion molecule induction: Involvement of an inhibitory G protein
-
Sadeghi MM, Collinge M, Pardi R, Bender JR. Simvastatin modulates cytokine-mediated endothelial cell adhesion molecule induction: involvement of an inhibitory G protein. J Immunol 2000;165: 2712-8. (Pubitemid 30660721)
-
(2000)
Journal of Immunology
, vol.165
, Issue.5
, pp. 2712-2718
-
-
Sadeghi, M.M.1
Collinge, M.2
Pardi, R.3
Bender, J.R.4
-
52
-
-
0043166922
-
Lovastatin inhibits bone marrow-derived dendritic cell maturation and upregulates proinflammatory cytokine production
-
DOI 10.1016/S0008-8749(03)00148-5
-
Sun D, Fernandes G. Lovastatin inhibits bone marrow-derived dendritic cell maturation and upregulates proinflammatory cytokine production. Cell Immunol 2003;223:52-62. (Pubitemid 36945549)
-
(2003)
Cellular Immunology
, vol.223
, Issue.1
, pp. 52-62
-
-
Sun, D.1
Fernandes, G.2
-
53
-
-
0042930877
-
Inhibition of Rho family gtpases results in increased TNFalpha production after lipopolysaccharide exposure
-
Monick MM, Powers LS, Butler NS, Hunninghake GW. Inhibition of Rho family GTPases results in increased TNF-alpha production after lipopolysaccharide exposure. J Immunol 2003;171:2625-30. (Pubitemid 37025575)
-
(2003)
Journal of Immunology
, vol.171
, Issue.5
, pp. 2625-2630
-
-
Monick, M.M.1
Powers, L.S.2
Butler, N.S.3
Hunninghake, G.W.4
-
54
-
-
33646016282
-
Statin-induced proinflammatory response in mitogen-activated peripheral blood mononuclear cells through the activation of caspase-1 and IL-18 secretion in monocytes
-
Coward WR, Marei A, Yang A, Vasa-Nicotera MM, Chow SC. Statin-induced proinflammatory response in mitogen-activated peripheral blood mononuclear cells through the activation of caspase-1 and IL-18 secretion in monocytes. J Immunol 2006;176:5284-92.
-
(2006)
J Immunol
, vol.176
, pp. 5284-5292
-
-
Coward, W.R.1
Marei, A.2
Yang, A.3
Vasa-Nicotera, M.M.4
Chow, S.C.5
-
55
-
-
0034660687
-
Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma
-
Kunzmann V, Bauer E, Feurle J, Weissinger F, Tony HP, Wilhelm M. Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 2000;96:384-92. (Pubitemid 30463353)
-
(2000)
Blood
, vol.96
, Issue.2
, pp. 384-392
-
-
Kunzmann, V.1
Bauer, E.2
Feurle, J.3
Weissinger, F.4
Tony, H.-P.5
Wilhelm, M.6
-
56
-
-
0037968274
-
Gammadelta T cells for immune therapy of patients with lymphoid malignancies
-
DOI 10.1182/blood-2002-12-3665
-
Wilhelm M, Kunzmann V, Eckstein S, Reimer P, Weissinger F, Ruediger T, et al. Gammadelta T cells for immune therapy of patients with lymphoid malignancies. Blood 2003;102:200-6. (Pubitemid 36759655)
-
(2003)
Blood
, vol.102
, Issue.1
, pp. 200-206
-
-
Wilhelm, M.1
Kunzmann, V.2
Eckstein, S.3
Reimer, P.4
Weissinger, F.5
Ruediger, T.6
Tony, H.-P.7
-
57
-
-
0141567513
-
Induction of gammadelta T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo [3]
-
DOI 10.1182/blood-2003-05-1655
-
Dieli F, Gebbia N, Poccia F, Caccamo N, Montesano C, Fulfaro F, et al. Induction of gammadelta T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo. Blood 2003; 102:2310-1. (Pubitemid 37122416)
-
(2003)
Blood
, vol.102
, Issue.6
, pp. 2310-2311
-
-
Dieli, F.1
Gebbia, N.2
Poccia, F.3
Caccamo, N.4
Montesano, C.5
Fulfaro, F.6
Arcara, C.7
Valerio, M.R.8
Meraviglia, S.9
Di, S.C.10
Sireci, G.11
Salerno, A.12
-
58
-
-
34547638252
-
Targeting human gammadelta T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer
-
DOI 10.1158/0008-5472.CAN-07-0199
-
Dieli F, Vermijlen D, Fulfaro F, Caccamo N, Meraviglia S, Cicero G, et al. Targeting human gammadelta T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res 2007;67:7450-7. (Pubitemid 47206575)
-
(2007)
Cancer Research
, vol.67
, Issue.15
, pp. 7450-7457
-
-
Dieli, F.1
Vermijlen, D.2
Fulfaro, F.3
Caccamo, N.4
Meraviglia, S.5
Cicero, G.6
Roberts, A.7
Buccheri, S.8
D'Asaro, M.9
Gebbia, N.10
Salerno, A.11
Eberl, M.12
Hayday, A.C.13
-
59
-
-
77954652637
-
In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients
-
Meraviglia S, Eberl M, Vermijlen D, Todaro M, Buccheri S, Cicero G, et al. In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients. Clin Exp Immunol 2010;161:290-7.
-
(2010)
Clin Exp Immunol
, vol.161
, pp. 290-297
-
-
Meraviglia, S.1
Eberl, M.2
Vermijlen, D.3
Todaro, M.4
Buccheri, S.5
Cicero, G.6
-
60
-
-
50649102839
-
Phase-I study of Innacell gammadelta, an autologous cell-therapy product highly enriched in gamma9delta2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma
-
Bennouna J, Bompas E, Neidhardt EM, Rolland F, Philip I, Galéa C, et al. Phase-I study of Innacell gammadelta, an autologous cell-therapy product highly enriched in gamma9delta2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma. Cancer Immunol Immunother 2008;57:1599-609.
-
(2008)
Cancer Immunol Immunother
, vol.57
, pp. 1599-1609
-
-
Bennouna, J.1
Bompas, E.2
Neidhardt, E.M.3
Rolland, F.4
Philip, I.5
Galéa, C.6
-
61
-
-
77951296062
-
A phase I study of adoptive immunotherapy for recurrent non-small-cell lung cancer patients with autologous gammadelta T cells
-
Nakajima J, Murakawa T, Fukami T, Goto S, Kaneko T, Yoshida Y, et al. A phase I study of adoptive immunotherapy for recurrent non-small-cell lung cancer patients with autologous gammadelta T cells. Eur J Cardiothorac Surg 2010;37:1191-7.
-
(2010)
Eur J Cardiothorac Surg
, vol.37
, pp. 1191-1197
-
-
Nakajima, J.1
Murakawa, T.2
Fukami, T.3
Goto, S.4
Kaneko, T.5
Yoshida, Y.6
|